Dr. Reddy’s to delay semaglutide supplies due to quality isssue, shares hit

Dr. Reddy’s Laboratories is facing a setback as it has to delay the supply of semaglutide, the key ingredient in popular diabetes and weight loss drugs Wegovy and Ozempic, due to quality issues. This delay has led to a significant drop in the company's shares, indicating the drug's substantial market impact. The situation underscores the critical importance of maintaining high-quality standards in pharmaceutical manufacturing, especially for medications that have broad therapeutic applications and consumer reliance. The delay could affect patients relying on these medications, highlighting the broader implications for healthcare and supply chain management.